Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as a injectable solution for intravenous use. It treats certain advanced cancers, notably non‑small cell lung cancer and metastatic breast cancer, in adult patients.

GNH USA supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Vinorelbine is used in the treatment of solid tumours that depend on rapid cell division.

Non‑small cell lung cancer: improves disease control and overall survival in eligible patients. Metastatic breast cancer: provides tumour response and disease stabilization in patients who have received prior therapy. Other solid tumours: may be considered in specific protocols where vinorelbine is part of combination regimens.

Vinorelbine can cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Neutropenia (low white blood cell count) - Anemia - Fatigue - Alopecia (hair loss) - Constipation

Serious or Rare Side Effects: - Severe neutropenia with febrile infection - Pulmonary toxicity (interstitial pneumonitis) - Peripheral neuropathy - Hypersensitivity reactions including anaphylaxis - Hypotension during infusion - Cardiac arrhythmias

Before initiating therapy, clinicians should assess baseline organ function and monitor patients closely for toxicity.

Monitor blood counts: perform regular complete blood count to detect neutropenia. Assess liver function: adjust dosing if hepatic impairment is present. Evaluate pulmonary status: avoid in patients with pre‑existing severe lung disease. Use caution with concomitant myelosuppressive agents: increased risk of bone‑marrow suppression. Avoid in known hypersensitivity to vinorelbine or other Vinca alkaloids. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase vinorelbine exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Concurrent myelosuppressive chemotherapy: heightens risk of severe bone‑marrow toxicity. - Other Vinca alkaloids: additive neurotoxicity. - Monoclonal antibodies targeting the same pathway: potential overlapping toxicities.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Nephrotoxic agents (e.g., aminoglycosides): watch renal function. - Drugs causing QT prolongation: observe cardiac rhythm. - Herbal supplements affecting CYP enzymes (e.g., St John's wort): assess for altered metabolism.